Subcutaneous infliximab could ‘transform’ how patients with IBD navigate care

Subcutaneous infliximab achieved greater clinical remission and endoscopic response rates compared with placebo in patients with inflammatory bowel disease and has potential to become a more convenient, “patient-centric” treatment option.“Infliximab has been used in clinical practice for more than 20 years, and it is known to be one of the most effective IBD treatments,” Nam Lee, PhD, medical director in the department of medical affairs at Celltrion Healthcare, told Healio. “However, given the inconvenience of intravenous route of administration of infliximab, aRead More

Generated by Feedzy